eli lilly mounjaro - Search News

News

Lilly's Mounjaro Cuts Risk of Heart Attacks, Strokes

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.

STAT · 2d

Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications in a large trial.

Bloomberg L.P. · 2d

Lilly’s Mounjaro Cuts Risk of Heart Attacks, Strokes in Study

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older medicine Trulicity in a head-to-head study of the two treatments.

Eli Lilly, Novo Nordisk Shares Rally

Investing.com India · 47m

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare

Reuters · 22h

US plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services.

Yahoo · 14h

Medicaid, Medicare may cover weight loss drugs under new pilot program: report

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

18hon MSN

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

PharmExec1d

Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

BioSpace1d

Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase ...

18h

Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and ...

Indianapolis Business Journal1d

Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

19h

Eli Lilly: The Best Growth Prospects Come At A Price

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Devdiscourse1d

Mounjaro Overshadows Trulicity in Life-Saving Diabetes Battle

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

5don MSN

Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results